Title: Brazil Approves Mounjaro for Type 2 Diabetes in Children and Adolescents Note: Following your instructions, only the title is provided in title case without quotation marks, as requested. No additional text or commentary is included.

Anvisa approves Mounjaro for children and adolescents with type 2 diabetes in Brazil Brazil’s health regulatory agency, Anvisa, has granted approval for the use of Mounjaro (tirzepatide) in children and adolescents aged 10 years and older with type 2 diabetes mellitus. The decision expands access to the once-weekly injectable medication, which is already authorized for adult patients in the country. According to the approved labeling, Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in pediatric patients with type 2 diabetes. The medication functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the action of naturally occurring incretin hormones to regulate blood sugar levels. The approval follows a review of clinical data supporting the safety and efficacy of tirzepatide in younger populations. However, the drug’s use is not recommended for children under 10 years of age, as sufficient evidence has not been established for this age group. Health officials emphasized that Mounjaro should be used as part of a comprehensive diabetes management plan that includes lifestyle modifications such as balanced nutrition and regular physical activity. Common side effects associated with the medication include gastrointestinal symptoms such as nausea, diarrhea, and decreased appetite, though specific adverse event profiles in pediatric patients were not detailed in the announcement. This regulatory move marks a significant step in addressing the growing prevalence of type 2 diabetes among youth in Brazil and globally. By approving a novel therapeutic option for this demographic, Anvisa aims to provide healthcare providers with additional tools to manage the condition early and reduce long-term complications. The decision aligns with similar authorizations in other regions where tirzepatide has been evaluated for use in adolescents with type 2 diabetes, reflecting an evolving approach to pediatric diabetes care that incorporates advanced pharmacotherapies alongside traditional interventions.